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Key Points
• Sixty-two percent
(1450/2334) of newly
diagnosed MM patients
have unchanged renal
function at 12 months.
• The proportion of renal
function change from
baseline at 12 months
comprised 38%: 22%
improved and 16% had
a decline in renal
function.
Renal injury is a common complication of multiple myeloma (MM) and is associated with
adverseoutcome.Despite this, thenatural historyof renal injury inpatientswithMMremains
uncertain especially in the context of intensive therapy and novel therapies. To address the
lack of data, we evaluated the renal function of 2334 patients from the UK National Cancer
Research InstituteMyelomaXI trial at baseline and at 12months to assess renal function over
time and the factors associated with change. Patients who had severe acute kidney injury or
a requirement for dialysis were excluded. At 12 months of the 1450 evaluable patients
planned for autologous transplantation; 204 (14%) patients had a decline in estimated
glomerularfiltration rate (eGFR)$25% from baseline, 341 (23.5%) had an improvement and
905 (62%) had no significant change in eGFR. Renal outcome at 12 months for the 884
evaluable patients who were not planned for transplant was similar. Improved renal
function was more likely if patients were,70 years old, male, had an average eGFR,60 mL
perminute per 1.73m2 and a higher baseline free light chain level.1000mg/L, and/or a free
light chain response of .90%. It did not correlate with monoclonal–protein response,
transplantation, or use of a bortezomib-based regimen.We show that with current therapies
the proportion of patients who have a significant decline in renal function in the first 12
months is small. The greatest relative improvement in eGFR is seen in patients with high free
light chain at baseline and a high light chain response. This trial was registered at http://
www.isrctn.com as #49407852.
Introduction
Around 50% of patients with multiple myeloma (MM) have renal impairment (RI) at presentation as
defined by an estimated glomerular filtration rate (eGFR) ,60 mL per minute per 1.73 m2. Severe RI
(eGFR ,30 mL per minute per 1.73 m2) affects up to 20% and is associated with poorer outcomes.1-4
Many patients with severe RI have severe acute kidney injury (AKI; stage 3); some of these patients are
dialysis dependent at or shortly after presentation: in this group of patients, 1-year survival improves if
there is recovery of renal function.5-7 Many of these patients have myeloma cast nephropathy (MCN)
caused by high levels of serum free light chain (sFLC). With rapid reduction of sFLC, many patients with
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MCN will recover kidney function. However, most patients with
a low eGFR have chronic kidney disease (CKD) and mild to
moderate RI (eGFR, 30-59 mL per minute); in this group, the effect
of RI on long-term outcomes is uncertain. In addition, it is not known
what proportion of patients with mild to moderate RI have MCN as
a component of their RI.
Understanding the natural history of renal function in patients with
myeloma, including the impact of mild to moderate RI on clinical
outcomes in patients with MM, will become increasingly important
as long-term outcomes continue to improve. In many long-term
diseases, the baseline level of kidney function is a major determinant
of patient survival. Defining the contribution of kidney disease
stratified by severity on outcomes will inform discussions around
future therapy choices and overall long-term prognosis. In addition,
there has been no large-scale assessment of the relationship
between renal function change postinduction and sFLC at
presentation and the change in sFLC postinduction in patients
with mild to moderate RI at presentation.
To address this lack of knowledge on the impact of renal disease on
outcomes in the era of novel therapies and transplantation, we used
data from the Myeloma XI trial; the largest trial of newly
diagnosed MM (NDMM) patients to assess the renal function at
presentation and sFLC pre- and postinduction on 12-month renal
function and patient survival.
Methods
Myeloma XI trial patients
Myeloma XI was a phase 3, randomized, multicenter, parallel group
design, open-labeled trial of thalidomide, lenalidomide, carfilzomib,
and bortezomib induction combinations, with maintenance lenali-
domide6 vorinostat in NDMM patients with symptomatic myeloma.
A multicenter research ethics committee and local ethics commit-
tees approved the protocol and all patients gave written informed
consent in accordance with the Declaration of Helsinki. The main
trial results have been published elsewhere.8-10
The trial had 2 distinct treatment pathways: the intensive pathway,
which included younger patients in whom high-dose therapy with
stem cell support was deemed appropriate, and the nonintensive
pathway that included patients who were deemed unsuitable for
a transplant. In both pathways, patients were randomized to
induction therapy with cyclophosphamide, thalidomide, and dexa-
methasone (CTD) or cyclophosphamide lenalidomide and dexa-
methasone (CRD) and 6 cyclophosphamide, bortezomib,
dexamethasone (CVD) intensification in patients with suboptimal
response to CRD or CTD and treated to maximum response. In
a modification of the trial carfilzomib, cyclophosphamide, lenalido-
mide, and dexamethasone was used as induction compared with
the response adapted approach with CTD or CRD 6 CVD.
Posttransplant (or after the completion of induction if transplant
ineligible) patients were randomized to lenalidomide, lenalidomide
and vorinostat, or no maintenance treatment.
Patients aged 18 years or older with symptomatic new myeloma
were eligible to participate. Patients who required dialysis on
presentation or those with AKI, characterized by creatinine .500
mmol/L or urine output ,400 mL per day, that was unresponsive
following 72 hours of rehydration were excluded.8 The treatment
pathway was decided on an individual basis based on a combination
of the patient’s performance status, clinical judgment, and
participant preference.
Baseline characteristics
The baseline variables included age, ethnicity, gender, paraprotein
type (Sebia), serum creatinine (Roche) at baseline and at 12 6 3
months, and sFLC (Freelite assay from The Binding Site Ltd,
Birmingham, United Kingdom) at baseline and at 12 6 3 months.
eGFR was calculated using the Modification of Diet in Renal
Disease formula. Renal function was stratified according to level of
eGFR; eGFR .59 mL per minute per 1.73 m2, eGFR 30 to 59 mL
per minute per 1.73 m2, or an eGFR ,30 mL per minute per
1.73 m2.11
Renal outcome and hematological
response assessments
Patients who had baseline and 12-month eGFR results available at
the central laboratory database were included in the renal response
assessment (n 5 2334) (Figure 1). If a 12-month eGFR was not
available, then the closest sample taken within 63 months of
12 months was regarded as 12-month eGFR. Patients who did not
have a baseline eGFR (n5 265) or a 12-month follow-up sample (n
5 1768) were excluded from this analysis (Figure 1). Any positive or
negative change in eGFR ,25% at 12 months compared with
baseline was considered no change; change in eGFR $25% at
12 months compared with baseline was considered significant.12
Patients were categorized into 3 renal outcome groups; patients
who had a decline in eGFR ($25%), those who had an
improvement in eGFR ($25%), and patients who maintained their
renal function at 12 months (,25% change). Patients starting with
normal renal function (ie, eGFR $90 mL per minute per 1.73 m2)
were not included in the analysis of improvement.
Polyclonal sFLC concentrations increase progressively with de-
clining renal function.13 To provide a meaningful assessment of the
hematological disease response, only patients who had a difference
between the involved and the uninvolved free light chain serum
levels (dFLC) level .100 mg/L were included in the measurement
of the serum dFLC response.14 Patients with progression of their
myeloma were not excluded from analyses.
Statistical methods
Statistical analysis was performed using SPSS for Windows,
version 21.0 (SPSS Inc, Chicago, IL). Categorical variables were
summarized as frequencies and percentages. Comparison for
categorical variables among different groups was made with x2 test
and Fisher’s exact test where appropriate. Continuous variables
were expressed as median with interquartile range (IQR) for data
that was not normally distributed.
The Mann-Whitney U test was used to compare differences in age,
baseline eGFR, and baseline dFLC. The Kruskal-Wallis test was
used to compare differences in age, baseline eGFR, 12-month
eGFR, and baseline dFLC level in the 3 renal outcome groups
defined on the basis of change in eGFR. The association between
different baseline dFLC categories, dFLC response level, and the 3
renal outcome groups defined by change in eGFR was assessed by
x2 test.
Kaplan-Meier analyses were used to report patient survival, and the
curves were compared using the log-rank test. Logistic regression
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analysis was used to determine factors associated with renal
outcome. The outcome categories were based on changes in
eGFR from baseline to 12 months; therefore, problems associated
with mathematical coupling would have been introduced had
baseline eGFR level been included as an explanatory variable. For
continuous variables, under the assumption of equality of variances
of initial and final values, change and initial value are correlated, but
change and mean of initial and final values are not.15 For this reason,
eGFR levels based on an average of baseline and 12-month eGFR
were used in the regression model.
Results
Baseline characteristics
The Myeloma XI study enrolled 4420 patients; for 4158 patients,
the central laboratory analyses for these patients have been used in
the study. In total, 55% of patients presented with an eGFR$60mL
per minute per 1.73 m2. A total of 2435 (58.5%) patients were
assigned to the intensive pathway and 1723 (41.4%) to the
nonintensive pathway (Figure 1). Baseline characteristics are
shown (Table 1). Compared with the nonintensive pathway, patients
in the intensive pathway were younger, with a median age of
65 years (IQR, 70-59) vs 79 years (IQR, 75-83) (P, .001), and had
better renal function at presentation, median eGFR 68 mL per
minute per 1.73 m2 (IQR, 54-85) vs 58 mL per minute per 1.73 m2
(IQR, 44-75) (P , .001). Patients in the intensive pathway had
a significantly better dFLC response at 12 months; dFLC response
.90% of 36% compared with 21% in the nonintensive pathway
(P , .001).
For this analysis, the patients in the intensive and nonintensive
pathways were analyzed separately because of the significant
differences in baseline renal assessments. Overall RI defined by
eGFR ,60 mL per minute per 1.73 m2 at presentation was
reported in 39%; 32% patients in the intensive arm and 49%
patients in the nonintensive pathway (Table1). Eighty-nine (2.4%)
patients died with renal failure (myeloma related) as the primary
cause of death and 52% of these had an eGFR$45 mL per minute
per 1.73 m2 at diagnosis. Exact detailing required to clarify whether
these patients were offered dialysis or not was not available.
Renal function at recruitment for patients in the intensive pathway,
stratified according to eGFR were as follows; 1514 (62%) patients
had eGFR .59 mL per minute, 658 (27%) had eGFR of 30 to
59 mL per minute, and 122 (5%) patients had an eGFR,30 mL per
minute. In the nonintensive pathway, 757 (44%) patients had eGFR
.59 mL per minute, 708 (41%) had eGFR of 30 to 59 mL per
minute, and 134 (7.7%) had an eGFR,30 mL per minute (Table 1).
Renal outcome
Baseline and 12-month eGFR results were available for 2334
patients: 1450 in the intensive pathway and 884 in the nonintensive
pathway (Table 2).
Myeloma XI Trial
Intensive pathway
n= 2435
Non-intensive 
pathway
n=1723
eGFR
unavailable at
presentation
n= 141
eGFR
unavailable at
12+/-3 months
n= 959
eGFR
presentation and
12+/-3 months
n=1450 (60%)
115 patients
no presentation
and 12+/- 3
month eGFR
Died within first 15
months, n=138 (14%) 
eGFR available outside
12+/-3 months window,
n=604 (63%)
No follow up eGFR,
n=217 (23%)
Decline
in eGFR
n=204 (14%)
Improvement
in eGFR
n=341 (23%)
No change
in eGFR
n=905 (62%)
eGFR
unavailable at
presentation
n= 124
eGFR
unavailable at
12+/-3 months
n= 809
eGFR at
presentation and
12 +/-3 months
n=884 (51%)
94 patients
no presentation
and 12+/-3
month eGFR
Died within first 15
months, n=269 (33%) 
eGFR available outside
12+/-3 months window,
n=376 (46%)
No follow up eGFR,
n=164 (20%)
Decline
in eGFR
n=178 (20%)
Improvement
in eGFR
n=161 (18%)
No change
in eGFR
n=545 (62%)
Figure 1. National Cancer Research Institute Myeloma XI trial consort diagram showing patient distribution with a baseline and 12 6 3-month eGFR.
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In the intensive pathway at 12 months, 204 (14%) patients of the
1450 evaluable patients had a decline in eGFR ($25%) with
a median decline of 26 mL per minute per 1.73 m2 (IQR, 22-32),
341 (23.5%) had an improvement in eGFR ($25%) with a median
rise of 24 mL per minute per 1.73 m2 (IQR, 18-29), and 905 (62%)
did not have a significant change (Table 2). Patients who had an
improvement in eGFR at 12 months had a significantly lower
baseline eGFR (51 mL per minute per 1.73 m2 vs 80 mL per minute
Table 1. Baseline characteristics of patients recruited to Myeloma XI by treatment pathway
Characteristics Total Intensive pathway Nonintensive pathway P
N or n (%) 4158 2435 (58.5) 1723 (41.4)
Age, y
Median (IQR) 71 (78-64) 65 (70-59) 79 (83-75) <.001
Sex, n (%)
Male:female 2439 (59):1719 (41) 1462 (60):973 (40) 977 (57):746 (43) .031
Ethnicity, n (%)
White: others 3880 (93):278 (7) 2255 (93):180 (7) 1625 (94):98 (6) .199
Myeloma type, n (%)
IgG 2252 (54) 1296 (53) 956 (55.5) .001
IgA 919 (22) 519 (21) 400 (23.2)
LCO 491 (12) 325 (13) 166 (9.6)
No paraprotein 32 (0.8) 20 (0.8) 12 (0.7)
IgD 42 (1) 33 (1.4) 9 (0.5)
IgM 8 (0.2) 6 (0.2) 2 (0.1)
Missing 414 (10) 236 (9.7) 178 (10.4)
FLC isotype, n (%)
k 2449 (59) 1421 (58.4) 1028 (60) .177
l 1260 (30) 757 (31) 503 (29)
Missing 449 (11) 257 (10) 192 (11)
dFLC k, mg/L
Median (IQR) 320 (44-984) 292 (40-901) 370 (72.5-1124) .008
dFLC l, mg/L
Median (IQR) 406 (69-1127) 429 (69-1143) 380 (63-1098) .575
Baseline eGFR, mL per min per 1.73 m2
Median (IQR) 64 (49-81) 68 (54-85) 58 (44-75) <.001
Baseline eGFR, n (%), mL per min per 1.7 3 m2
eGFR .59 2271 (55) 1514 (62) 757 (44) <.001
eGFR 30-59 1366 (33) 658 (27) 708 (41)
eGFR ,30 256 (6.2) 122 (5) 134 (7.7)
Missing 265 (6.4) 141 (6) 124 (7)
Baseline dFLC, n (%), mg/L
,500 2314 (56) 1379 (57) 935 (54) <.001
500-1000 596 (14) 356 (15) 240 (14)
$1001 995 (24) 559 (23) 436 (25)
Missing 253 (6) 141 (6) 112 (6.5)
dFLC response, n (%)
,50% 125 (3) 34 (1.4) 91 (5.2) <.001
50%-90% 290 (7) 86 (3.5) 204 (12)
.90% 1239 (30) 879 (36.1) 360 (21)
Baseline dFLC ,100 1160 (28) 718 (29.4) 442 (25.6)
Missing 1344 (32) 718 (29.4) 626 (36.3)
Boldface P values signify statistical significance (P , .05).
Ig, immunoglobulin; LCO, light chain only.
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per 1.73 m2 in the decline group and 75 mL per minute per 1.73 m2
in the no change group, P , .001). Patients who had improvement
in eGFR also had a significantly higher proportion of patients with
baseline dFLC of more than 1000 mg/L (37% vs 18% in the decline
group and 20% with no change; P , .001), and significantly more
patients achieved .90% dFLC response (69.2% vs 53% in the
decline group and 57% in the no change group; P 5 .001)
(Table 2). Age was not significantly different in the 3 renal outcome
groups in the intensive arm. In the 14% of patients who had
a significant decline in their renal function, the majority (70%) had
a baseline dFLC ,500 mg/L (Table 2) and the decline was not
associated with higher FLC levels or a lack of FLC response
(Table 2).
In the nonintensive pathway, the changes in renal function identified
at 12 months were similar to those in the intensive pathway
(Table 2). A total of 178 (20%) of 884 evaluable patients had
a decline in their eGFR, with a median decline of 26 mL per minute
per 1.73 m2 (IQR, 19-33), 161 (18%) had an improvement in their
eGFR with a median rise in this group of 19 mL per minute per
1.73 m2 (IQR, 15-25), and in 545 (62%), patients’ renal function
was maintained. The factors associated with renal outcome in the
nonintensively treated patients were also similar to those in the
intensive pathway. Patients who had an improvement in their eGFR
at 12 months had a lower starting eGFR (45 mL per minute per
1.73 m2 compared with 72 mL per minute per 1.73 m2 in the decline
group, and 62 mL per minute per 1.73 m2 in the no change group,
P , .001), a higher proportion of patients with baseline dFLC of
more than 1000 mg/L (34% vs 20% in the decline group and 23%
in the no change group, P 5 .07), and had a higher proportion of
patients achieving .90% dFLC response (44.7% in the improve-
ment group compared with 32% in the decline group and 39.6% in
the no change group, P 5 .002) (Table 2). In the 20% of patients
who had a significant decline in their renal function, the majority
(64%) had a baseline dFLC ,500 mg/L (Table 2).
Multivariate analysis
In a multivariate analyses using a logistic regression model (Table 3)
patients were more likely to have had an improvement in renal
function if they were;,70 years of age (odds ratio [OR], 1.58; 95%
confidence interval [CI], 1.23-2.04; P , .001), male (OR, 1.62;
95% CI, 1.26-2.09; P , .001), had an average eGFR ,60 mL per
minute (OR, 2.23; 95% CI, 1.73-2.87; P , .001) compared with
eGFR$60 mL per minute, baseline dFLC.1000 mg/L (OR, 1.69;
95% CI, 1.28-2.22; P , .001) compared with baseline dFLC
,500 mg/L and dFLC response .90% (OR, 1.92; 95% CI, 1.11-
3.34; P 5 .02) compared with dFLC response ,50%. Factors
associated with a decline in eGFR at 12 months were dFLC
response ,50% (OR, 2.54, 95% CI, 1.64-3.94; P , .001) and
female sex (OR, 1.42; 95% CI, 1.08-1.88; P 5 .01).
In a univariate analysis, we found that patients who underwent stem
cell transplantation, were less likely to have a decline in kidney
function at 12 months (OR, 0.637; 95% CI, 0.50-0.81; P , .001)
compared with those who did not. However, this was not of
significance in a multivariate analysis.
Survival analysis
The median follow-up for the series as a whole cohort was
30.5 months (95% CI, 29.38-31.658). The median overall survival
for the series as a whole was 60 months (95% CI, 57-63); 407
(10%) died in the first 12 months. Median survival was longer in
patients recruited to the intensive arm compared with the
nonintensive arm, 64 months (95% CI, 61-67) vs 44 months
(95% CI, 41-48), P , .01, respectively. The median survival by
baseline eGFR was 64 months (95% CI, 61-67) for baseline eGFR
.59 mL per minute; 64 months (95% CI, 59-69) for eGFR 30 to
Table 3. Univariate and multivariate analysis of factors associated
with improvement and decline in renal function at 12 mo
Variables
Univariate analysis Multivariable analysis
OR (95% CI) P OR (95% CI) P
Improvement
Age, y .007 <.001
,70 1.31 (1.07-1.60) 1.58 (1.23-2.04)
$70 Reference Reference
Sex .009 <.001
Male 1.37 (1.08-1.75) 1.62 (1.26-2.09)
Female Reference Reference
Baseline dFLC, mg/L
.1000 1.98 (1.53-2.57) <.001 1.69 (1.28-2.22) <.001
500-1000 1.06 (0.77-1.46) <.001 0.98 (0.70-1.36) <.001
,500 Reference .70 Reference .91
Average eGFR, mL/min
,30 2.90 (1.82-4.64) <.001 3.35 (1.96-5.73) <.001
30-59 1.69 (1.37-2.08) <.001 2.23 (1.73-2.87) <.001
$60 Reference <.001 Reference <.001
dFLC response, %
.90 2.01 (1.18-3.42) .012 1.92 (1.11-3.34) .04
50-90 1.53 (0.84-2.75) .010 1.55 (0.84-2.84) .02
,50 Reference .15 Reference .15
Decline
Age, y .001 .05
,70 0.70 (0.54-0.84) 0.74 (0.55-1.00)
$70 Reference Reference
Sex .002 .01
Female 1.41 (1.12-1.75) 1.42 (1.08-1.88)
Male Reference Reference
Baseline dFLC, mg/L .14
,500 1.37 (0.99-1.88) .05 1.33 (0.95-1.86) .22
500-1000 1.18 (0.80-1.73) .39 1.23 (0.82-1.83) .08
.1000 Reference Reference .30
Average eGFR, mL/min
,30 1.17 (0.65-2.13) .15 1.12 (0.55-2.26) .78
30-59 1.25 (0.99-1.58) .59 1.10 (0.82-1.49) .74
$60 Reference .05 Reference .50
dFLC response, %
.90 0.34 (0.22-0.52) <.001 0.39 (0.20-0.60) <.001
50-90 0.32 (0.19-0.55) <.001 0.34 (0.20-0.57) <.001
,50 Reference <.001 Reference <.001
All ORs have been quoted relative to the reference categories. Boldface P values signify
statistical significance (P , .05).
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59 mL per minute; 44 months (95% CI, 34-53) for eGFR ,30 mL
per minute, P , .001 (Figure 2). The median survival in patients
stratified by eGFR level at 12 months was significantly better in
those with eGFR $30 mL per minute compared with patients with
eGFR ,30 mL per minute; 64 months (95% CI, 57-72) vs
55 months (95% CI, 43-67), P , .001 (Figure 3).
Missing data
A full dataset was not available for 1824 patients, and 411 patients
died within the first 15 months and hence were not evaluable for
renal outcome analysis. Of the 1413 remaining patients without
a 12-month or baseline eGFR, 1005 (71%) patients had a follow-up
eGFR recorded outside the window of 9 to 15 months and were
therefore not included in the 12-month follow-up dataset.
In the intensive pathway, 985 patients did not have a baseline or 12-
month eGFR results and were excluded from analysis (Figure 1).
There were 242 (24.5%) deaths in this group. A total of 236 (24%)
of 985 patients in the intensive pathway had an available eGFR at
more than 15 months; in this group, there were 37 (17%) deaths;
199 were censored. Of the 236 patients, 203 had both a baseline
and an eGFR result at .15 months compared with baseline, 60%
had no change in renal function, 19% had a decline, and 22% had
an improvement. In the 749 patients who did not have a.15-month
available eGFR, there were 205 (27%) deaths; 544 were censored.
In the nonintensive pathway, 839 patients did not have a baseline or
12-month eGFR (Figure 1). There were 401 (48%) deaths in this
group. A total of 155 of 839 patients had an available eGFR at more
than 15 months; in this group, there were 42 (27%) deaths and 113
were censored. Of the 155 patients, 110 had a baseline and an
available eGFR at .15 months; compared with baseline, 60% had
no change in renal function, 20% had a decline, and 20% had an
improvement. In the 684 patients who did not have .15-month
eGFR, there were 359 (52%) deaths; 325 were censored.
Hematological response and renal outcome
There was no difference in the proportion of patients achieving
complete response vs partial response vs no change in the 3 renal
response groups (supplemental Table 1). Of the 1450 evaluable
patients in the intensive pathway, 890 (61%) underwent autologous
stem cell transplant (ASCT). The proportion of patients who had
a renal decline vs no change vs renal improvement was no different
in patients who underwent ASCT compared with no ASCT in those
treated in the intensive pathway (supplemental Table 2).
Value of proteasome inhibitor bortezomib
Patients with a suboptimal response to standard induction
treatment (CTD(a)/CRD(a)) were randomized to CVD vs nothing.
Of the 2334 evaluable patients, 367 were randomized to CVD, 226
from the intensive pathway and 141 from the nonintensive pathway.
The response post-CVD and renal outcome in 121 patients in the
intensive pathway and in 65 from the nonintensive pathway was
similar and not statistically significant (supplemental Table 3).
Discussion
Overall, we show that the renal prognosis at 12-months for patients
presenting with MM is good, with a relatively small proportion having
a significant decline. Change in renal function at 12 months does
not appear to affect patient survival; patients who recover renal
function are more likely to be ,70 years of age, male, have a lower
mean GFR, higher baseline dFLC levels, and .90% clonal
response, suggesting that this group are more likely to have
myeloma cast nephropathy.
This large study, which included patients with all levels of renal
function down to an eGFR of 15 mL per minute, showed that renal
impairment (eGFR ,60 mL per minute per 1.73 m2) is common in
NDMM affecting around one-half of all patients.16 We show that
62% (1450/2334) of NDMM patients had unchanged renal
function at 12 months; 38% had significant change from baseline,
with 22% (502/2334) of patients had an improvement and 16%
(382/2334) had a decline.
The variables associated with improvement in renal function at
12 months were younger patients (age,70 years), male sex, higher
baseline free light chain levels (.1000 mg/L), lower average
glomerular filtration rate (,60 mL per minute per 1.73 m2), and
eGFR level at baseline with
total number of patients (N)
and deaths in each
category.
eGFR >59 ml/min:
N 1422, Deaths 243 (17%)
eGFR 30-59 ml/min:
N 777, Deaths 155 (20%)
eGFR <30 ml/min:
N 116, Deaths 40 (34%)
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Figure 2. Kaplan-Meier plot comparing overall
survival between patients with different eGFR
levels at baseline. Overall survival was significantly
longer among those with baseline eGFR $30 mL per
minute compared with those with eGFR ,30 mL per
minute (P , .001).
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.90% clonal response. There was no correlation with M-protein
response, transplantation, or use of a bortezomib-based regimen.
The analysis took account of patients in the 2 treatment pathways
separately because there were significant differences in the
approach to treatment and difference in overall patient survival.
When comparing the 3 renal outcome groups, no advantage in
overall survival was found for patients with improvement in renal
function. The current findings enhance the results of a study that
looked at the effect of RI on outcomes after ASCT in MM, which
reported no difference in overall and progression-free survival in the
3 groups.17 In this study, patients were categorized into 3 groups:
no RI at diagnosis and ASCT, RI at diagnosis with normalization
before ASCT, and RI both at time of diagnosis and ASCT.
Analysis of renal outcome at 12 months from the start of treatment
showed that for the majority of patients (62%) renal function did not
change. Patients presenting with light chains .500 mg/L are more
likely to develop cast nephropathy.18,19 This occurs because of
a heavy load of filtered free light chains that escape tubular
reabsorption and coprecipitate with Tamm–Horsfall protein in the
distal nephron causing intratubular obstruction, but rapid treatment
can result in improvement in renal function.20 In our study, patients
who had an improvement in renal function at 12 months started with
higher baseline dFLC and had lower mean eGFR, suggesting that
these patients were more likely to have reversible myeloma cast
nephropathy. In addition, there was an independent relationship
between improvement in kidney function and the strength of
disease remission as measured by dFLC response.
Decline in eGFR at 12 months was seen in relatively few patients
(16% overall). Lack of timely clonal response is known to result in
accelerated renal fibrosis.21 Our study showed that lack of dFLC
response was independently associated with worse renal outcome.
Being female was the other factor; however, gender differences are
not explained because the clonal responses were not different
between men and women. The Myeloma IX study reported on sex-
dependent differences in the prevalence of the primary genetic
events of myeloma, and secondary genetic events were more
frequent in women. Female sex was also associated with inferior
overall survival. The study concluded that higher prevalence of
lesions associated with poor prognosis in the female myeloma
population may adversely affect clinical outcome.22
There are several potential limitations of this study, which may affect
conclusions about the proportion of patients affected by CKD. The
current criteria for renal response have been defined by the
International Myeloma Working Group (IMWG).23-27 Using the
IMWG criteria, a complete renal response is defined as a sustained
(ie, $2 months) improvement of baseline eGFR from ,50 mL per
minute to $60 mL per minute, renal partial response as sustained
improvement of baseline eGFR from ,15 mL per minute to 30 to
59 mL per minute, renal minor response as an improvement from
,15 mL per minute to 15 to 29 mL/min or if baseline eGFR was 15
to 29 mL per minute and improved to 30 to 59 mL per minute.23 By
IMWG criteria, only 5% in the intensive and 4.5% in the
nonintensive pathway met the criteria for a complete response
renal. Because patients with severe RI and patients on dialysis were
excluded from the trial, we could not make conclusions regarding
the proportion of patients with partial response renal and minor
response renal. Therefore, we chose a $25% change in eGFR as
the definition for change in renal function.12 The definition of a renal
response may change with time as the relationship between renal
function and long-term outcomes are better defined, and this study
may contribute to this.
A shortfall is that current diagnostic guidelines for MM do not
include the presence of proteinuria, which was not available for this
study. Proteinuria data may help to differentiate between AKI
resulting from cast nephropathy and CKD and would be valuable to
correlate with outcomes and renal responses in future studies.
The strengths of this study comprised broad inclusion criteria
ensuring that the data are useful for the interpretation of the natural
history of myeloma patients on a population basis, biochemical data
derived from a single central laboratory ensuring the accuracy and
reproducibility of the results generated, and detailed sFLC data.
Median: 64 months
Median: 64 months
Median: 55 months
eGFR level at 12 months
with total number (N) of
patients and deaths in 
each category.
eGFR >59 ml/min,
N 1398, Deaths 235 (17%)
eGFR 30-59 ml/min,
N 878, Deaths 181 (21%)
eGFR <30 ml/min,
N 92, Deaths 34 (37%)
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Figure 3. Kaplan-Meier plot comparing overall
survival between patients with different eGFR
levels at 12 months. Overall survival was significantly
longer among those with 12-month eGFR $30 mL per
minute compared with those with eGFR ,30 mL per
minute (P , .001).
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The majority of NDMM patients present with mild to moderate RI.
The aim of this study was to investigate renal outcomes at
12 months from myeloma presentation. We show that renal
prognosis in patients who present with MM and an eGFR
.15 mL per minute is good. In patients with an eGFR of $30 mL
per minute, renal function is not an independent determinant of 12-
month outcome. Improvement in renal function is more likely in
patients who present with very high light chains, suggesting
reversibility of kidney disease in those patients with cast nephrop-
athy. Depth of light chain response is independently associated with
both renal response and renal progression. Further work is now
required to assess the effect of RI on longer term outcomes and to
reassess renal response criteria in patients with MM.
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